Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2007

View Archived Issues

Low-dose, high-dose intensity decitabine beneficial in myelodysplastic syndrome

Erythrocyte Gs: a novel target for the treatment of malaria

Selegiline skin patch studied for smoking cessation

Pharmion reflects on 2006, milestones for 2007

Labopharm's once-daily tramadol rolled out across Europe

Novel inhibitors of Rho kinase profiled at GlaxoSmithKline

Genentech acquires oncology program from Amphora Discovery

Organon collaborates with Huya Bioscience

AVI and Eleos sign crosslicense agreement for p53 antisense drugs

Alnylam and Inex to use liposomal delivery technology for RNAi therapeutics

Ceftobiprole meets endpoints in pivotal complicated skin infections study

Cannabinoids reduce melanoma growth

Combinations with pazopanib produce synergistic cytotoxicity in multiple myeloma

Acid sphingomyelinase replacement therapy to be evaluated in Niemann-Pick disease

Recent Pfizer patents disclose novel analgesic agents

Recent Merck KGaA patent describes new therapeutic agents for skin hyperpigmentation

New antidiabetic agents disclosed in recent patent literature

Xytis cleared to begin phase II study of anatibant for traumatic brain injury

Phase III study evaluates Axid OS for use in infants with GERD

Napo to acquire intellectual property, plans financing

BG-12 begins phase III for relapsing-remitting MS

Phase II trials in China to study Rh-Apo2L in cancer

Phase III program under way for cetrorelix in BPH

AL-108 to be studied for cognitive impairment in schizophrenia

rEV-131 misses primary endpoint in phase II postcataract inflammation trial

Cell Therapeutics updates progress of Xyotax and pixantrone programs

Biopure receives opinion letter in U.K. on Hemopure MAA

Italian Ministry of Health requests Iplex be made available for ALS

Recentin announced as global trademark for AZD-2171

InteKrin licenses INT-131 from Amgen

Japanese filing for mirtazapine planned for mid-2007

Solvay and Wyeth expand neuroscience agreement into antipsychotic research

SPA offered for Ark's phase III study of Trinam

First launch for hepatitis B vaccine Supervax in Argentina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...